Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
BioCryst Pharmaceuticals
Biotech
BioCryst scraps eye drug to focus on rare diseases
BioCryst announced it has ended development of avoralstat, which was being studied to treat diabetic macular edema.
Will Maddox
May 6, 2026 10:40am
BioCryst inks $700M Astria deal to rival Takeda in rare disease
Oct 14, 2025 10:30am
Novo Nordisk nominates CEO successor—Chutes & Ladders
Aug 1, 2025 8:30am
BMS vet answers Foghorn’s call for CBO—Chutes & Ladders
Sep 6, 2024 8:30am
45 days later, BioCryst abandons another drug, citing competition
Dec 15, 2022 10:29am
BioCryst leaves ultra-rare disease efforts in hands of peers
Nov 1, 2022 10:00am
